Literature DB >> 45128

Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations.

H M Calil, D H Avery, L E Hollister, I Creese, S H Snyder.   

Abstract

A new dopamine radioreceptor assay was used to measure serum concentrations of neuroleptics during treatment of 58 patients. Results of this assay are expressed as chlorpromazine equivalents. Serum concentrations varied with different drugs, with extremely high levels in patients receiving thioridazine or mesoridazine. No detectable serum levels were found in 11 patients, probably either due to low drug doses or noncompliance in taking medication. Best results with the assay were obtained in the 22 patients treated with haloperidol. Serum concentrations of haloperidol were correlated with dose and were related to the Brief Psychiatric Rating Scale (BPRS) total pathology score, as well as to BPRS factor scores for thinking disturbance and paranoid disturbance. Serum concentrations of haloperidol were not different among patients with or without the presence of extrapyramidal symptoms or among patients receiving or not receiving concurrent antiparkinson medication.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 45128     DOI: 10.1016/0165-1781(79)90026-x

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

1.  Psychiatry: indications for monitoring psychotherapeutic drug concentrations.

Authors:  J R Magliozzi
Journal:  West J Med       Date:  1985-05

2.  Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.

Authors:  L T Kucharski; P Alexander; L Tune; J Coyle
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 3.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

4.  A unitary mechanism of calcium antagonist drug action.

Authors:  K M Murphy; R J Gould; B L Largent; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

5.  Antiemetic effect of haloperidol in the dog as related to plasma level and dose.

Authors:  C J Niemegeers; J J Heykants; P A Janssen
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Dopamine, serotonin and alpha-adrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long-term chlorpromazine treatment.

Authors:  T Nakahara; M Hirano; H Uchimura; M Saito; J S Kim; T Matsumoto; H Yokoo; M Shimomura; A Mukai
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

7.  Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.

Authors:  J G Csernansky; J Kaplan; C A Holman; L E Hollister
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

8.  Haloperidol plasma levels and clinical response in paranoid schizophrenics.

Authors:  P Linkowski; P Hubain; R von Frenckell; J Mendlewicz
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

9.  Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.

Authors:  M L Rao; W A Brown
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.